Última actualización 18 de julio de 2026
Key finding
HbA1c decreased from 8.17 ± 0.10 to 7.46 ± 0.15 (P<0.001)
The study investigated the addition of vildagliptin to premixed insulin therapy in patients with type 2 diabetes, finding significant improvements in glycemic control.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The study investigated the addition of vildagliptin to premixed insulin therapy in patients with type 2 diabetes, finding significant improvements in glycemic control.
Effective management of blood sugar levels is crucial for patients with type 2 diabetes to prevent complications. The addition of vildagliptin to insulin therapy offers a promising strategy to enhance glycemic control, potentially improving patient outcomes and quality of life.
Limited generalizability due to specific population characteristics Short duration of the study may not capture long-term effects Potential for unmeasured confounders affecting outcomes
Published in
Publication details and source links for this paper.
Deyue K, Ziyang S, Lanlan J, et al. Vildagliptin Added to Premixed Insulin Therapy Improves Glycemic Control in Patients with Type 2 Diabetes. Frontiers in Endocrinology. 2025;16:1508918. doi:10.3389/fendo.2025.1508918
HbA1c decreased from 8.17% to 7.46% (P<0.001)
Mean blood glucose decreased from 10.7 mmol/L to 8.82 mmol/L (P<0.001)
Time in target range increased from 45.64% to 64.22% (P<0.001)
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Insulin therapy and Area under the curve (AUC) for blood glucose levels above 3.9, Blood glucose, Glucose iAUC (OGTT), and 5 more.
This study contributes evidence to
Primary intervention
Insulin therapy
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
8
Evidence pairs
573
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Relación de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Insulin therapy → Area under the curve (AUC) for blood glucose levels above 3.9
Insulin therapy → Area under the curve (AUC) for blood glucose levels above 3.9
Insulin therapy → Mean amplitude of glycemic excursions (MAGE)
Insulin therapy → Mean amplitude of glycemic excursions (MAGE)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Therapies and HbA1c, Insulin Therapies and Postprandial and OGTT Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on Insulin Therapies
Contributes to Insulin Therapies evidence base.
All studies measuring Postprandial and OGTT Glucose
Measures Postprandial and OGTT Glucose as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
4 results
3 results
4 results
4 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
Insulin Therapies may improve CGM Time in Range.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Time in range
EvidenceScore™ Strong | EvidenceScore™ 77.4 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Time above range
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 9 supporting studies with generally consistent results and a positive effect signal.
Limitations
Insulin Therapies may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
Insulin Therapies appears to improve Fasting Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Blood glucose
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
Insulin Therapies appears to improve Postprandial and OGTT Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Glucose iAUC (OGTT)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
